Roche Acquires 89bio for Up to $3.5 Billion to Enhance Liver Disease Treatment Portfolio

On September 18, 2025, Roche Holding AG announced its agreement to acquire U.S.-based biotech firm 89bio Inc. for a total of up to $3.5 billion. The deal involves an upfront payment of $14.50 per share, representing a nearly 80% premium over 89bio's closing price prior to the announcement, and includes contingent value rights (CVRs) that could add up to $6 per share based on future milestones. This acquisition positions Roche to expand its portfolio in the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a liver disease increasingly linked to obesity.

89bio (ETNB) Stock Soars as Roche Announces $3.5 Billion Acquisition DealReutersRoche To Buy 89bio in $3.5 Billion DealSTAT (News)CTechBioPharmaDive

Founded in 2018, 89bio specializes in therapies for liver and cardiometabolic diseases. Its lead drug candidate, pegozafermin, is an FGF21 analogue currently in late-stage development for MASH, a condition characterized by liver fat accumulation that can lead to inflammation and fibrosis. MASH has become a significant health concern, affecting millions and often resulting in severe complications such as cirrhosis and liver transplants. Roche's acquisition underscores the growing interest in innovative treatments for this condition, particularly as the market for obesity-related therapies expands.

Roche to acquire 89bio in a deal worth up to US$3.5bn

Roche's CEO, Thomas Schinecker, emphasized that the acquisition strengthens the company's focus on cardiovascular, renal, and metabolic diseases. He noted that pegozafermin's distinct mechanism of action could potentially offer "best-in-disease efficacy" for patients with moderate to severe MASH. The company is also exploring the possibility of combining pegozafermin with its existing weight-loss drug candidates, enhancing its competitive edge in the obesity treatment market.

Roche to acquire 89bio in a deal worth up to US$3.5bnInvestor's Business DailyRoche to Acquire 89bio and Phase 3 MASH Candidate in Potential $3.5B DealBioPharmaDiveCTech

The acquisition of 89bio is part of a broader trend among pharmaceutical companies to invest in obesity-related therapeutics. In recent months, other major players like GSK and Novo Nordisk have made significant moves in this space, highlighting the competitive landscape for MASH treatments. Analysts have noted that Roche's investment in 89bio reflects a strategic bet on the potential success of pegozafermin, which is currently undergoing Phase 3 trials, with results expected in 2027 and 2028.

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

Despite the optimism surrounding the acquisition, some analysts caution that the market potential for pegozafermin remains uncertain. RBC Capital Markets analyst Brian Abrahams noted that while the drug is promising, its market utilization potential is still to be determined. Following the announcement, shares of 89bio surged approximately 86%, indicating strong investor confidence in the acquisition.

BioPharmaDive

Roche's Teresa Graham stated, "This acquisition further strengthens our portfolio in cardiovascular, renal, and metabolic diseases and offers opportunities to explore combinations with existing programmes in our pipeline." Meanwhile, Roche's commitment to advancing therapies for obesity-related conditions was reiterated, as the company continues to seek innovative solutions for complex health challenges.

Roche to acquire 89bio in a deal worth up to US$3.5bn

The acquisition is expected to close in the fourth quarter of 2025, pending customary closing conditions. As Roche integrates 89bio into its Pharmaceuticals Division, the focus will shift to advancing pegozafermin through clinical trials and exploring its potential as a transformative treatment option for MASH.

Roche to Acquire 89bio and Phase 3 MASH Candidate in Potential $3.5B Deal